{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000822","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.152537+00:00","generated_at":"2026-06-15T04:22:16.550237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edgewise Therapeutics reports Q1 2023 net loss of $22.8M; cash at $328M; advancing EDG-5506 and EDG-7500 trials","bullets":["Net loss of $22.8M ($0.36 per share) vs $19.4M in prior quarter; R&D spend rose to $19.9M.","Cash, cash equivalents and marketable securities of $328M as of March 31, 2023.","Advancing Phase 2 CANYON (BMD) and LYNX (DMD) trials for EDG-5506; interim DMD data expected Q4 2023.","IND-enabling studies for EDG-7500 (HCM) ongoing; Phase 1 start expected in 2H2023.","Plan to add registration-enabling cohort in CANYON in 2H2023; 12-month ARCH data expected Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000822","json":"https://secwatch.observer/filing/0001157523-23-000822.json","markdown":"https://secwatch.observer/filing/0001157523-23-000822.md","text":"https://secwatch.observer/filing/0001157523-23-000822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/0001157523-23-000822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/a53398173.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:22:16.550237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc0f4cb111af8a04ae07d68cd4ce7a8d7c8ae55c","claim":"Edgewise Therapeutics, Inc. reported financial results for first quarter of 2023.","evidence_excerpt":"Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323000822/0001157523-23-000822-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}